FTC case against insulin price gouging halted after commissioners fired by Trump
A Federal Trade Commission (FTC) case against insulin price gouging has come to a screeching halt after two Democratic commissioners were fired by President Donald Trump.
On March 31, the FTC stayed its suit against pharmacy middle managers, called pharmacy benefit managers (PBMs). Government investigations, including one by the FTC, have pointed to PBMs, as behind at least part of the high prices.
The FTC said in its order that the case couldn’t move ahead because the remaining two Republican commissioners had recused themselves.
Related articles
-
News BriefFTC pushes back timeline for ‘Click to Cancel’ Rule, raising compliance questions
The Federal Trade Commission was set to begin enforcement of the “click to cancel” rule on May 14, but a new announcement from the agency pushed that date to July 14. As is the case with many of the regulatory decisions by the Trump administration, it’s unclear whether the agency ...
-
News BriefFTC rule forces fee transparency in ticketing and lodging industries
Ticketing and short-term lodging businesses will be prohibited from hiding “convenience” and other fees from consumers under a rule by the Federal Trade Commission (FTC), set to take effect next week.
-
News BriefFTC sues Uber over deceptive subscriptions, a rare move for consumers by Trump officials
The Federal Trade Commission (FTC) filed a lawsuit against Uber, alleging the ride-hailing company signed customers up for its Uber One subscription without consent, then made it hard for them to cancel. The move marks the U.S. government’s latest broadside against big tech companies, and the first major action from ...
More from Regulatory Enforcement
-
News BriefCFPB drops $95M enforcement action against Navy Federal, without explanation
The Consumer Financial Protection Bureau has dropped a $95 million enforcement action against Navy Federal Credit Union, the latest regulatory pullback by the agency under President Donald Trump.
-
ArticleFCA drops ‘naming and shaming’ approach – except in ‘exceptional circumstances’
The UK’s financial regulator has had a rough ride over the past couple of years as its strategy to “name and shame” firms it opened investigations into was widely slammed by the industry and lawmakers over concerns that companies could be unfairly maligned.
-
News BriefDOJ targets $14.6B in health care fraud with focus on transnational crime
Emerging enforcement priorities of the U.S. Department of Justice’s health care fraud division align with the Trump administration’s emphasis on prosecuting transnational criminal organizations and ending opioid trafficking.